Alumis Insider Buying: CEO and Legal Officer Grab 186,200 Stock Options, Boosting Investor Confidence
Alumis insider option buys signal long‑term confidence amid volatile shares—key to future upside.
3 minutes to read
Alumis Inc
New FDA‑Approved Oncology Therapies Show Survival Gains & Lower Toxicity
Explore the latest FDA‑approved oncology drugs—Tegafur‑S‑1, CAR‑T, Pembrolizumab + chemo, and TDM‑1—showing survival gains, safety, and precision‑medicine insights.
4 minutes to read
Foresite Capital Buys Alumis Shares, Signaling Confidence in TYK2 Pipeline
Foresite Capital’s recent purchase of Alumis Inc. shares signals strong institutional confidence in its TYK2 inhibitor pipeline, offering investors insight into a clinical‑stage biotech’s future prospects.
4 minutes to read